Pacific Biosciences of California, Inc. (PACB)

Pacific Biosciences (often called PacBio) is an instrumentation and services company in the genomics space. It manufactures sequencing machines that read DNA in longer stretches than competing technologies, which has proven valuable for certain research and diagnostic applications. The company sells both hardware and ongoing consumables—reagents and chips—to research institutions, diagnostics labs, and pharmaceutical companies worldwide.

The sequencing platform business

PacBio’s core offering is its Sequel sequencing instrument and the ecosystem of software, protocols, and support around it. The instrument uses a technology called single-molecule, real-time sequencing (SMRT) to read DNA fragments thousands of base pairs long, far longer than the short reads that other sequencing platforms produce. This long-read capability is particularly useful for resolving complex genomic regions, detecting structural variants, and assembling genomes de novo.

The business model mirrors other life-sciences instrumentation companies: sell the machine at a margin, then earn recurring revenue from the customer’s ongoing purchase of consumables—the flow cells, reagents, and other supplies needed to run the instrument month after month. The installed base of active sequencers drives consumables revenue, the most profitable stream. A customer who buys one Sequel instrument becomes an annuity for years if they remain engaged.

Service and data analysis

PacBio has expanded beyond selling hardware into offering sequencing as a service. The company operates facilities where customers send samples and PacBio runs the sequencing, then returns the data. This model changes the revenue character: instead of selling machines and waiting for consumables purchases, PacBio captures margin on the entire value chain. It is higher risk—the company must manage lab operations, quality, and turnaround time—but also higher reward if executed well.

The company also bundles software and bioinformatics tools with its instruments, helping customers extract meaning from the raw sequencing data. These software tools are increasingly sophisticated, addressing analysis workflows that would otherwise require customers to build or license from third parties.

The diagnostics and clinical market

Beyond research, PacBio has pursued clinical diagnostics applications—using long-read sequencing to detect genetic diseases, identify copy-number variations, and support rare-disease diagnosis. This segment is slower-growing than research but carries higher regulatory barriers and longer sales cycles. Success requires navigating clinical laboratory regulation, health reimbursement coverage, and clinician adoption. PacBio has made progress here but faces competition from established diagnostic firms and alternative sequencing approaches.

Cyclicality and adoption drivers

The genomics instrumentation market is sensitive to both research funding and the pace at which institutions adopt new technologies. In periods of robust public funding for life sciences—such as when governments increase research budgets or large grants flow—demand for sequencing tools rises. In downturns, research spending often contracts faster than biotech revenue, creating volatility for instrumentation companies.

Long-read sequencing, meanwhile, competes with cheaper short-read alternatives from competitors like Illumina and others. The value proposition is real—long reads solve specific problems—but adoption requires that the benefit justify the cost difference. As long-read technology matures and prices decline, the addressable market expands. Until then, growth depends on winning customers who value the specific advantages PacBio’s approach provides.

Competition and market position

PacBio competes in a market dominated by larger, well-funded players. Illumina has the largest installed base of sequencers globally and enormous brand recognition in research labs. Oxford Nanopore offers long-read sequencing via a different technology at lower upfront cost. Smaller players like 10x Genomics and others address adjacent parts of the genomics workflow.

PacBio’s advantage is the quality and length of its reads and a growing ecosystem of workflows built around its platform. Its disadvantage is scale—it is smaller, has a narrower installed base, and cannot match larger competitors’ R&D spending or customer-support infrastructure. The company’s viability rests on maintaining its technical advantage while expanding the commercial segments that can support long-read sequencing economically.

Research and development spending

PacBio invests heavily in R&D to advance its sequencing chemistry, improve read accuracy and length, reduce costs per run, and expand into new applications. This spending is necessary to stay competitive but also limits near-term profitability. The company has historically run with modest operating margins or losses, reinvesting capital into product improvement and market development.

How to research Pacific Biosciences

Start with the annual 10-K filing (SEC CIK 0001299130) to understand revenue breakdown by segment (research instruments, service, diagnostics), the installed base of instruments, gross margins on hardware and consumables, and the pipeline of development programs. Quarterly earnings calls reveal trends in adoption, customer feedback, and management’s confidence in market adoption timelines.

Key metrics: installed base growth, consumables revenue per active instrument, average selling price of instruments, customer retention and churn, and gross margin trends. Compare PacBio’s read length, accuracy, and cost per gigabase to competing platforms. Monitor clinical diagnostic approvals and reimbursement progress, as clinical adoption could be a significant growth driver. Follow industry publications and researcher commentary on the long-read sequencing market to assess whether the technology is gaining adoption or losing ground to alternatives.